An international group of researchers believe there is enough evidence that anti-malarial drugs could be repurposed to treat COVID-19 and that they should be assessed for efficacy in clinical trials. The review article, published online in Trends in Parasitology, outlines the evidence for the antiviral and anti-inflammatory properties of certain anti-malarial drugs that could play a role in tackling COVID-19. The research group, from institutions across Europe, Asia and Africa, point to a combination of the drugs artesunate and pyronaridine as the most promising. Both drugs have demonstrated antiviral effects on the SARS-CoV-2 virus in human lung cells in laboratory...